Dr. Napatalung is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Union Square E
Suite 4J
New York, NY 10003Phone+1 212-844-8800Fax+1 212-844-8801
Education & Training
- Mayo Clinic College of Medicine and Science (Scottsdale)Residency, Dermatology, 2013 - 2016
- Mayo Clinic College of Medicine and ScienceInternship, Transitional Year, 2012 - 2013
- University of Tennessee Health Science Center College of MedicineClass of 2012
Certifications & Licensure
- NY State Medical License 2017 - 2026
- IL State Medical License 2016 - 2020
- AZ State Medical License 2013 - 2018
- American Board of Dermatology Dermatology
Publications & Presentations
PubMed
- Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study.Yuji Yamaguchi, Elena Peeva, Roni Adiri, Pranab Ghosh, Lynne Napatalung
Journal of the American Academy of Dermatology. 2024-12-19 - A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia are...Samira Anderson, Guido Cavaletti, Linda J Hood, Michael Polydefkis, David N Herrmann
Pharmacology Research & Perspectives. 2024-08-01 - The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995-2016.Sissel Brandt Toft Sørensen, Prethibha George, Oladayo Jagun, Robert Wolk, Lynne Napatalung
Dermatology and Therapy. 2024-04-01
Press Mentions
- A New Frontier to Fight This Hair-Loss DiseaseMarch 1st, 2021
- Practical Considerations in Pediatric AlopeciaAugust 29th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: